Immunome Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of Immunome Inc.'s 2024 Annual Meeting of Stockholders held on June 12, 2024. The record date for the meeting was April 25, 2024, with 59,943,368 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors
- Clay B. Siegall, Ph.D.: Elected with 43,295,914 votes for, 80,139 votes withheld, and 6,682,195 broker non-votes.
- Carol A. Schafer: Elected with 33,452,580 votes for, 9,923,473 votes withheld, and 6,682,195 broker non-votes.
- Both directors were elected to serve until the 2027 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2024.
- Voting Results: 50,008,641 votes for, 29,664 votes against, and 19,943 abstentions. There were no broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (59,943,368) against the company's most recent 10-Q or 10-K to confirm capitalization changes.
- Note the significant number of broker non-votes (6,682,195) on the director election, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the tenure of the newly elected directors (Clay B. Siegall and Carol A. Schafer) extends through the 2027 Annual Meeting.
- Verify the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024.